APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumors Target Proteins

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Solid Tumors Target Proteins Market Analysis and Forecast 2026-2032

Report ID 174036800227 December 2025191 pages

Choose your research edition.

Industry ResearchSolid Tumors Target Proteins Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumors Target Proteins Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Solid Tumors Target Proteins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumors Target Proteins Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumors Target Proteins Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Solid Tumors Target Proteins market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Solid Tumors Target Proteins is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Solid Tumors Target Proteins is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Solid Tumors Target Proteins is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Solid Tumors Target Proteins is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Solid Tumors Target Proteins include Novartis, Sino Biological, ACRO Biosystems, TargetMol Chemicals, ProteoGenix, Kite Pharma, Kactus Biosystems, Juno Therapeutics and Elabscience, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Solid Tumors Target Proteins, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Solid Tumors Target Proteins, also provides the revenue of main regions and countries. Of the upcoming market potential for Solid Tumors Target Proteins, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Solid Tumors Target Proteins revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Solid Tumors Target Proteins market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Solid Tumors Target Proteins revenue, projected growth trends, production technology, application and end-user industry.

Solid Tumors Target Proteins Segment by Company

Novartis

Sino Biological

ACRO Biosystems

TargetMol Chemicals

ProteoGenix

Kite Pharma

Kactus Biosystems

Juno Therapeutics

Elabscience

Creative BioMart

Creative Biolabs

Bio-Techne

Bio X Cell

ACROBiosystems

Solid Tumors Target Proteins Segment by Type

EGFR Protein

HER2 Protein

Others

Solid Tumors Target Proteins Segment by Application

Hospital

Biological Laboratory

Others

Solid Tumors Target Proteins Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumors Target Proteins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumors Target Proteins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumors Target Proteins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Solid Tumors Target Proteins in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Solid Tumors Target Proteins company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Solid Tumors Target Proteins revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Solid Tumors Target Proteins Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. EGFR Protein Major Player Table 3. HER2 Protein Major Player Table 4. Others Major Player Table 5. Global Solid Tumors Target Proteins Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Biological Laboratory Major Player Table 8. Others Major Player Table 9. Solid Tumors Target Proteins Industry Trends Table 10. Solid Tumors Target Proteins Industry Drivers Table 11. Solid Tumors Target Proteins Industry Opportunities and Challenges Table 12. Solid Tumors Target Proteins Industry Restraints Table 13. Global Solid Tumors Target Proteins Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Solid Tumors Target Proteins Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Solid Tumors Target Proteins Market Share by Region (2021-2026) Table 16. Global Solid Tumors Target Proteins Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Solid Tumors Target Proteins Market Share by Region (2027-2032) Table 18. Global Solid Tumors Target Proteins Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Solid Tumors Target Proteins Revenue Market Share by Players (2021-2026) Table 20. Global Solid Tumors Target Proteins Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Solid Tumors Target Proteins Key Players Headquarters & Area Served Table 22. Global Solid Tumors Target Proteins Players, Product Type & Application Table 23. Global Solid Tumors Target Proteins Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Solid Tumors Target Proteins by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Solid Tumors Target Proteins Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Solid Tumors Target Proteins Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Solid Tumors Target Proteins Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Solid Tumors Target Proteins Revenue Market Share by Type (2021-2026) Table 30. Global Solid Tumors Target Proteins Revenue Market Share by Type (2027-2032) Table 31. Global Solid Tumors Target Proteins Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Solid Tumors Target Proteins Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Solid Tumors Target Proteins Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Solid Tumors Target Proteins Revenue Market Share by Application (2021-2026) Table 35. Global Solid Tumors Target Proteins Revenue Market Share by Application (2027-2032) Table 36. Novartis Company Information Table 37. Novartis Business Overview Table 38. Novartis Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Novartis Solid Tumors Target Proteins Product Portfolio Table 40. Novartis Recent Development Table 41. Sino Biological Company Information Table 42. Sino Biological Business Overview Table 43. Sino Biological Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sino Biological Solid Tumors Target Proteins Product Portfolio Table 45. Sino Biological Recent Development Table 46. ACRO Biosystems Company Information Table 47. ACRO Biosystems Business Overview Table 48. ACRO Biosystems Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. ACRO Biosystems Solid Tumors Target Proteins Product Portfolio Table 50. ACRO Biosystems Recent Development Table 51. TargetMol Chemicals Company Information Table 52. TargetMol Chemicals Business Overview Table 53. TargetMol Chemicals Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. TargetMol Chemicals Solid Tumors Target Proteins Product Portfolio Table 55. TargetMol Chemicals Recent Development Table 56. ProteoGenix Company Information Table 57. ProteoGenix Business Overview Table 58. ProteoGenix Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. ProteoGenix Solid Tumors Target Proteins Product Portfolio Table 60. ProteoGenix Recent Development Table 61. Kite Pharma Company Information Table 62. Kite Pharma Business Overview Table 63. Kite Pharma Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Kite Pharma Solid Tumors Target Proteins Product Portfolio Table 65. Kite Pharma Recent Development Table 66. Kactus Biosystems Company Information Table 67. Kactus Biosystems Business Overview Table 68. Kactus Biosystems Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Kactus Biosystems Solid Tumors Target Proteins Product Portfolio Table 70. Kactus Biosystems Recent Development Table 71. Juno Therapeutics Company Information Table 72. Juno Therapeutics Business Overview Table 73. Juno Therapeutics Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Juno Therapeutics Solid Tumors Target Proteins Product Portfolio Table 75. Juno Therapeutics Recent Development Table 76. Elabscience Company Information Table 77. Elabscience Business Overview Table 78. Elabscience Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Elabscience Solid Tumors Target Proteins Product Portfolio Table 80. Elabscience Recent Development Table 81. Creative BioMart Company Information Table 82. Creative BioMart Business Overview Table 83. Creative BioMart Solid Tumors Target Proteins Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Creative BioMart Solid Tumors Target Proteins Product Portfolio Table 85. Creative BioMart Recent Development Table 86. Creative Biolabs Company Information Table 87. Creative Biolabs Business Overview Table 88. Creative Biolabs Solid Tumors Target Proteins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Creative Biolabs Solid Tumors Target Proteins Product Portfolio Table 90. Creative Biolabs Recent Development Table 91. Bio-Techne Company Information Table 92. Bio-Techne Business Overview Table 93. Bio-Techne Solid Tumors Target Proteins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bio-Techne Solid Tumors Target Proteins Product Portfolio Table 95. Bio-Techne Recent Development Table 96. Bio X Cell Company Information Table 97. Bio X Cell Business Overview Table 98. Bio X Cell Solid Tumors Target Proteins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Bio X Cell Solid Tumors Target Proteins Product Portfolio Table 100. Bio X Cell Recent Development Table 101. ACROBiosystems Company Information Table 102. ACROBiosystems Business Overview Table 103. ACROBiosystems Solid Tumors Target Proteins Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. ACROBiosystems Solid Tumors Target Proteins Product Portfolio Table 105. ACROBiosystems Recent Development Table 106. North America Solid Tumors Target Proteins Revenue by Type (2021-2026) & (US$ Million) Table 107. North America Solid Tumors Target Proteins Revenue by Type (2027-2032) & (US$ Million) Table 108. North America Solid Tumors Target Proteins Revenue by Application (2021-2026) & (US$ Million) Table 109. North America Solid Tumors Target Proteins Revenue by Application (2027-2032) & (US$ Million) Table 110. North America Solid Tumors Target Proteins Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Solid Tumors Target Proteins Revenue by Country (2021-2026) & (US$ Million) Table 112. North America Solid Tumors Target Proteins Revenue by Country (US$ Million) & (2027-2032) Table 113. Europe Solid Tumors Target Proteins Revenue by Type (2021-2026) & (US$ Million) Table 114. Europe Solid Tumors Target Proteins Revenue by Type (2027-2032) & (US$ Million) Table 115. Europe Solid Tumors Target Proteins Revenue by Application (2021-2026) & (US$ Million) Table 116. Europe Solid Tumors Target Proteins Revenue by Application (2027-2032) & (US$ Million) Table 117. Europe Solid Tumors Target Proteins Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe Solid Tumors Target Proteins Revenue by Country (2021-2026) & (US$ Million) Table 119. Europe Solid Tumors Target Proteins Revenue by Country (US$ Million) & (2027-2032) Table 120. China Solid Tumors Target Proteins Revenue by Type (2021-2026) & (US$ Million) Table 121. China Solid Tumors Target Proteins Revenue by Type (2027-2032) & (US$ Million) Table 122. China Solid Tumors Target Proteins Revenue by Application (2021-2026) & (US$ Million) Table 123. China Solid Tumors Target Proteins Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Solid Tumors Target Proteins Revenue by Type (2021-2026) & (US$ Million) Table 125. Asia Solid Tumors Target Proteins Revenue by Type (2027-2032) & (US$ Million) Table 126. Asia Solid Tumors Target Proteins Revenue by Application (2021-2026) & (US$ Million) Table 127. Asia Solid Tumors Target Proteins Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Solid Tumors Target Proteins Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Asia Solid Tumors Target Proteins Revenue by Region (US$ Million) & (2021-2026) Table 130. Asia Solid Tumors Target Proteins Revenue by Region (US$ Million) & (2027-2032) Table 131. SAMEA Solid Tumors Target Proteins Revenue by Type (2021-2026) & (US$ Million) Table 132. SAMEA Solid Tumors Target Proteins Revenue by Type (2027-2032) & (US$ Million) Table 133. SAMEA Solid Tumors Target Proteins Revenue by Application (2021-2026) & (US$ Million) Table 134. SAMEA Solid Tumors Target Proteins Revenue by Application (2027-2032) & (US$ Million) Table 135. SAMEA Solid Tumors Target Proteins Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. SAMEA Solid Tumors Target Proteins Revenue by Country (2021-2026) & (US$ Million) Table 137. SAMEA Solid Tumors Target Proteins Revenue by Country (US$ Million) & (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Solid Tumors Target Proteins Image Figure 2. Global Solid Tumors Target Proteins Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Tumors Target Proteins Market Size Share 2021 VS 2025 VS 2032 Figure 4. EGFR Protein Image Figure 5. HER2 Protein Image Figure 6. Others Image Figure 7. Global Solid Tumors Target Proteins Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Solid Tumors Target Proteins Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Biological Laboratory Image Figure 11. Others Image Figure 12. Global Solid Tumors Target Proteins Market Size (US$ Million) & (2021-2032) Figure 13. Global Solid Tumors Target Proteins Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Solid Tumors Target Proteins Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Solid Tumors Target Proteins Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Solid Tumors Target Proteins Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Solid Tumors Target Proteins Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Solid Tumors Target Proteins Revenue Market Share by Type (2021-2032) Figure 20. Global Solid Tumors Target Proteins Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Solid Tumors Target Proteins Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Solid Tumors Target Proteins Revenue Market Share by Application (2021-2032) Figure 23. North America Solid Tumors Target Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Solid Tumors Target Proteins Revenue Share by Type (2021-2032) Figure 25. North America Solid Tumors Target Proteins Revenue Share by Application (2021-2032) Figure 26. North America Solid Tumors Target Proteins Revenue Share by Country (2021-2032) Figure 27. United States Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Solid Tumors Target Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Solid Tumors Target Proteins Revenue Share by Type (2021-2032) Figure 32. Europe Solid Tumors Target Proteins Revenue Share by Application (2021-2032) Figure 33. Europe Solid Tumors Target Proteins Revenue Share by Country (2021-2032) Figure 34. Germany Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Solid Tumors Target Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Solid Tumors Target Proteins Revenue Share by Type (2021-2032) Figure 44. China Solid Tumors Target Proteins Revenue Share by Application (2021-2032) Figure 45. Asia Solid Tumors Target Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Solid Tumors Target Proteins Revenue Share by Type (2021-2032) Figure 47. Asia Solid Tumors Target Proteins Revenue Share by Application (2021-2032) Figure 48. Asia Solid Tumors Target Proteins Revenue Share by Region (2021-2032) Figure 49. Japan Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Solid Tumors Target Proteins Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Solid Tumors Target Proteins Revenue Share by Type (2021-2032) Figure 57. SAMEA Solid Tumors Target Proteins Revenue Share by Application (2021-2032) Figure 58. SAMEA Solid Tumors Target Proteins Revenue Share by Country (2021-2032) Figure 59. Brazil Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Solid Tumors Target Proteins Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • EGFR Protein
  • HER2 Protein
  • Others
Applications
  • Hospital
  • Biological Laboratory
  • Others
Companies covered
  • Novartis
  • Sino Biological
  • ACRO Biosystems
  • TargetMol Chemicals
  • ProteoGenix
  • Kite Pharma
  • Kactus Biosystems
  • Juno Therapeutics
  • Elabscience
  • Creative BioMart
  • Creative Biolabs
  • Bio-Techne
  • Bio X Cell
  • ACROBiosystems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Solid Tumors Target Proteins Market by Type
  3. 1.2.1 Global Solid Tumors Target Proteins Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 EGFR Protein
  5. 1.2.3 HER2 Protein
  6. 1.2.4 Others
  7. 1.3 Solid Tumors Target Proteins Market by Application
  8. 1.3.1 Global Solid Tumors Target Proteins Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Biological Laboratory
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Solid Tumors Target Proteins Market Dynamics
  1. 2.1 Solid Tumors Target Proteins Industry Trends
  2. 2.2 Solid Tumors Target Proteins Industry Drivers
  3. 2.3 Solid Tumors Target Proteins Industry Opportunities and Challenges
  4. 2.4 Solid Tumors Target Proteins Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Solid Tumors Target Proteins Market Perspective (2021-2032)
  2. 3.2 Global Solid Tumors Target Proteins Growth Trends by Region
  3. 3.2.1 Global Solid Tumors Target Proteins Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Solid Tumors Target Proteins Market Size by Region (2021-2026)
  5. 3.2.3 Global Solid Tumors Target Proteins Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Solid Tumors Target Proteins Revenue by Players
  2. 4.1.1 Global Solid Tumors Target Proteins Revenue by Players (2021-2026)
  3. 4.1.2 Global Solid Tumors Target Proteins Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Solid Tumors Target Proteins Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Solid Tumors Target Proteins Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Solid Tumors Target Proteins Key Players Headquarters & Area Served
  7. 4.4 Global Solid Tumors Target Proteins Players, Product Type & Application
  8. 4.5 Global Solid Tumors Target Proteins Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Solid Tumors Target Proteins Market CR5 and HHI
  11. 4.6.3 2025 Solid Tumors Target Proteins Tier 1, Tier 2, and Tier 3
5 Solid Tumors Target Proteins Market Size by Type
  1. 5.1 Global Solid Tumors Target Proteins Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Solid Tumors Target Proteins Revenue by Type (2021-2032)
  3. 5.3 Global Solid Tumors Target Proteins Revenue Market Share by Type (2021-2032)
6 Solid Tumors Target Proteins Market Size by Application
  1. 6.1 Global Solid Tumors Target Proteins Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Solid Tumors Target Proteins Revenue by Application (2021-2032)
  3. 6.3 Global Solid Tumors Target Proteins Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Solid Tumors Target Proteins Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Sino Biological
  8. 7.2.1 Sino Biological Company Information
  9. 7.2.2 Sino Biological Business Overview
  10. 7.2.3 Sino Biological Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sino Biological Solid Tumors Target Proteins Product Portfolio
  12. 7.2.5 Sino Biological Recent Developments
  13. 7.3 ACRO Biosystems
  14. 7.3.1 ACRO Biosystems Company Information
  15. 7.3.2 ACRO Biosystems Business Overview
  16. 7.3.3 ACRO Biosystems Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ACRO Biosystems Solid Tumors Target Proteins Product Portfolio
  18. 7.3.5 ACRO Biosystems Recent Developments
  19. 7.4 TargetMol Chemicals
  20. 7.4.1 TargetMol Chemicals Company Information
  21. 7.4.2 TargetMol Chemicals Business Overview
  22. 7.4.3 TargetMol Chemicals Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  23. 7.4.4 TargetMol Chemicals Solid Tumors Target Proteins Product Portfolio
  24. 7.4.5 TargetMol Chemicals Recent Developments
  25. 7.5 ProteoGenix
  26. 7.5.1 ProteoGenix Company Information
  27. 7.5.2 ProteoGenix Business Overview
  28. 7.5.3 ProteoGenix Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  29. 7.5.4 ProteoGenix Solid Tumors Target Proteins Product Portfolio
  30. 7.5.5 ProteoGenix Recent Developments
  31. 7.6 Kite Pharma
  32. 7.6.1 Kite Pharma Company Information
  33. 7.6.2 Kite Pharma Business Overview
  34. 7.6.3 Kite Pharma Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Kite Pharma Solid Tumors Target Proteins Product Portfolio
  36. 7.6.5 Kite Pharma Recent Developments
  37. 7.7 Kactus Biosystems
  38. 7.7.1 Kactus Biosystems Company Information
  39. 7.7.2 Kactus Biosystems Business Overview
  40. 7.7.3 Kactus Biosystems Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Kactus Biosystems Solid Tumors Target Proteins Product Portfolio
  42. 7.7.5 Kactus Biosystems Recent Developments
  43. 7.8 Juno Therapeutics
  44. 7.8.1 Juno Therapeutics Company Information
  45. 7.8.2 Juno Therapeutics Business Overview
  46. 7.8.3 Juno Therapeutics Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Juno Therapeutics Solid Tumors Target Proteins Product Portfolio
  48. 7.8.5 Juno Therapeutics Recent Developments
  49. 7.9 Elabscience
  50. 7.9.1 Elabscience Company Information
  51. 7.9.2 Elabscience Business Overview
  52. 7.9.3 Elabscience Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Elabscience Solid Tumors Target Proteins Product Portfolio
  54. 7.9.5 Elabscience Recent Developments
  55. 7.10 Creative BioMart
  56. 7.10.1 Creative BioMart Company Information
  57. 7.10.2 Creative BioMart Business Overview
  58. 7.10.3 Creative BioMart Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Creative BioMart Solid Tumors Target Proteins Product Portfolio
  60. 7.10.5 Creative BioMart Recent Developments
  61. 7.11 Creative Biolabs
  62. 7.11.1 Creative Biolabs Company Information
  63. 7.11.2 Creative Biolabs Business Overview
  64. 7.11.3 Creative Biolabs Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Creative Biolabs Solid Tumors Target Proteins Product Portfolio
  66. 7.11.5 Creative Biolabs Recent Developments
  67. 7.12 Bio-Techne
  68. 7.12.1 Bio-Techne Company Information
  69. 7.12.2 Bio-Techne Business Overview
  70. 7.12.3 Bio-Techne Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bio-Techne Solid Tumors Target Proteins Product Portfolio
  72. 7.12.5 Bio-Techne Recent Developments
  73. 7.13 Bio X Cell
  74. 7.13.1 Bio X Cell Company Information
  75. 7.13.2 Bio X Cell Business Overview
  76. 7.13.3 Bio X Cell Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bio X Cell Solid Tumors Target Proteins Product Portfolio
  78. 7.13.5 Bio X Cell Recent Developments
  79. 7.14 ACROBiosystems
  80. 7.14.1 ACROBiosystems Company Information
  81. 7.14.2 ACROBiosystems Business Overview
  82. 7.14.3 ACROBiosystems Solid Tumors Target Proteins Revenue and Gross Margin (2021-2026)
  83. 7.14.4 ACROBiosystems Solid Tumors Target Proteins Product Portfolio
  84. 7.14.5 ACROBiosystems Recent Developments
8 North America
  1. 8.1 North America Solid Tumors Target Proteins Revenue (2021-2032)
  2. 8.2 North America Solid Tumors Target Proteins Revenue by Type (2021-2032)
  3. 8.2.1 North America Solid Tumors Target Proteins Revenue by Type (2021-2026)
  4. 8.2.2 North America Solid Tumors Target Proteins Revenue by Type (2027-2032)
  5. 8.3 North America Solid Tumors Target Proteins Revenue Share by Type (2021-2032)
  6. 8.4 North America Solid Tumors Target Proteins Revenue by Application (2021-2032)
  7. 8.4.1 North America Solid Tumors Target Proteins Revenue by Application (2021-2026)
  8. 8.4.2 North America Solid Tumors Target Proteins Revenue by Application (2027-2032)
  9. 8.5 North America Solid Tumors Target Proteins Revenue Share by Application (2021-2032)
  10. 8.6 North America Solid Tumors Target Proteins Revenue by Country
  11. 8.6.1 North America Solid Tumors Target Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Solid Tumors Target Proteins Revenue by Country (2021-2026)
  13. 8.6.3 North America Solid Tumors Target Proteins Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Solid Tumors Target Proteins Revenue (2021-2032)
  2. 9.2 Europe Solid Tumors Target Proteins Revenue by Type (2021-2032)
  3. 9.2.1 Europe Solid Tumors Target Proteins Revenue by Type (2021-2026)
  4. 9.2.2 Europe Solid Tumors Target Proteins Revenue by Type (2027-2032)
  5. 9.3 Europe Solid Tumors Target Proteins Revenue Share by Type (2021-2032)
  6. 9.4 Europe Solid Tumors Target Proteins Revenue by Application (2021-2032)
  7. 9.4.1 Europe Solid Tumors Target Proteins Revenue by Application (2021-2026)
  8. 9.4.2 Europe Solid Tumors Target Proteins Revenue by Application (2027-2032)
  9. 9.5 Europe Solid Tumors Target Proteins Revenue Share by Application (2021-2032)
  10. 9.6 Europe Solid Tumors Target Proteins Revenue by Country
  11. 9.6.1 Europe Solid Tumors Target Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Solid Tumors Target Proteins Revenue by Country (2021-2026)
  13. 9.6.3 Europe Solid Tumors Target Proteins Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Solid Tumors Target Proteins Revenue (2021-2032)
  2. 10.2 China Solid Tumors Target Proteins Revenue by Type (2021-2032)
  3. 10.2.1 China Solid Tumors Target Proteins Revenue by Type (2021-2026)
  4. 10.2.2 China Solid Tumors Target Proteins Revenue by Type (2027-2032)
  5. 10.3 China Solid Tumors Target Proteins Revenue Share by Type (2021-2032)
  6. 10.4 China Solid Tumors Target Proteins Revenue by Application (2021-2032)
  7. 10.4.1 China Solid Tumors Target Proteins Revenue by Application (2021-2026)
  8. 10.4.2 China Solid Tumors Target Proteins Revenue by Application (2027-2032)
  9. 10.5 China Solid Tumors Target Proteins Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Solid Tumors Target Proteins Revenue (2021-2032)
  2. 11.2 Asia Solid Tumors Target Proteins Revenue by Type (2021-2032)
  3. 11.2.1 Asia Solid Tumors Target Proteins Revenue by Type (2021-2026)
  4. 11.2.2 Asia Solid Tumors Target Proteins Revenue by Type (2027-2032)
  5. 11.3 Asia Solid Tumors Target Proteins Revenue Share by Type (2021-2032)
  6. 11.4 Asia Solid Tumors Target Proteins Revenue by Application (2021-2032)
  7. 11.4.1 Asia Solid Tumors Target Proteins Revenue by Application (2021-2026)
  8. 11.4.2 Asia Solid Tumors Target Proteins Revenue by Application (2027-2032)
  9. 11.5 Asia Solid Tumors Target Proteins Revenue Share by Application (2021-2032)
  10. 11.6 Asia Solid Tumors Target Proteins Revenue by Country
  11. 11.6.1 Asia Solid Tumors Target Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Solid Tumors Target Proteins Revenue by Country (2021-2026)
  13. 11.6.3 Asia Solid Tumors Target Proteins Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Solid Tumors Target Proteins Revenue (2021-2032)
  2. 12.2 SAMEA Solid Tumors Target Proteins Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Solid Tumors Target Proteins Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Solid Tumors Target Proteins Revenue by Type (2027-2032)
  5. 12.3 SAMEA Solid Tumors Target Proteins Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Solid Tumors Target Proteins Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Solid Tumors Target Proteins Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Solid Tumors Target Proteins Revenue by Application (2027-2032)
  9. 12.5 SAMEA Solid Tumors Target Proteins Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Solid Tumors Target Proteins Revenue by Country
  11. 12.6.1 SAMEA Solid Tumors Target Proteins Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Solid Tumors Target Proteins Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Solid Tumors Target Proteins Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst